

Washington Apple Health (Medicaid)

Substance Use Disorder Billing Guide (Fee-for-Service)

July 1, 2018

Every effort has been made to ensure this guide's accuracy. If an actual or apparent conflict between this document and an agency rule arises, the agency rules apply.



About this guide^{*}

This publication takes effect July 1, 2018, and supersedes earlier guides to this program.

HCA is committed to providing equal access to our services. If you need an accommodation or require documents in another format, please call 1-800-562-3022. People who have hearing or speech disabilities, please call 711 for relay services.

Washington Apple Health means the public health insurance programs for eligible Washington residents. Washington Apple Health is the name used in Washington State for Medicaid, the children's health insurance program (CHIP), and stateonly funded health care programs. Washington Apple Health is administered by the Washington State Health Care Authority.

^{*} This publication is a billing instruction.

Subject	Change	Reason for Change
All	Washington Administrative Code (WAC) references, language, terminology, and hyperlinks updated to reflect the transfer of the Behavioral Health Authority from the Department of Social and Health Services (DSHS) to the Health Care Authority, and the transfer of licensing from DSHS to the Department of Health (DOH). The transfer and the new WACs take effect on July 1, 2018.	Complies with <u>House</u> <u>Bill 1388</u>
Definitions	Definitions of opiate substitution treatment (OST) services and Provider Entry Portal (PEP) updated.	Clarification
	Definition of secure detoxification (secure detox) added.	Policy change adding secure detox as a covered service
	Definition of withdrawal management expanded to include acute and sub-acute.	Clarification
<u>Who should use</u> <u>this billing guide?</u>	Language added to clarify that providers using this guide should be registered with PEP.	Clarification
<u>Who should NOT</u> <u>use this billing</u> guide?	Information about managed care organizations (MCOs) removed, and a hyperlink to the list of MCOs in the Client Eligibility section of the guide added.	Clarification
How do I verify a <u>client's eligibility?</u>	"Blue box" note added about verifying eligibility for incarcerated clients added.	Clarification
	"Blue box" note added to remind providers that coverage can change at any time and to check eligibility at each visit.	Clarification
Behavioral Health Organization (BHO)	Language changed to reflect that as of July 1, 2018, the Health Care Authority is managing the contracts for the BHOs. There is no change in billing with this transfer.	Complies with <u>House</u> <u>Bill 1388</u> , which transfers the Behavioral Health Authority from the Department of Social and Health Services to the Health Care Authority

What has changed?

Subject	Change	Reason for Change
Coverage Table	Table updated with HCPCS short descriptions, and language that is more descriptive added under the "Service" column.	Consistency and clarification
	 HCPCS added as follows: H0010 for youth sub-acute withdrawal management H0011 for youth acute withdrawal management H0018 for adult recovery house H0019 for residential treatment, long term recovery 	Policy change and clarification
	Modifier description added for modifier HB.	Clarification
<u>How do I bill</u> <u>claims</u> <u>electronically?</u>	Language added that the instructions relate to billing Substance Use Disorder program services on a professional claim form.	Clarification
<u>Secure</u> Detoxification	Section added for secure detox services.	Policy change adding secure detox as a covered service

How can I get agency provider documents?

To access provider alerts, go to the agency's provider alerts web page.

To access provider documents, go to the agency's <u>provider billing guides and fee schedules</u> web page.

Copyright disclosure

Current Procedural Terminology (CPT) copyright 2017 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

P

Table of Contents

About this guide	
What has changed?	
How can I get agency provider documents?	5
Resources Available	7
Definitions	8
Substance Use Disorder Treatment	12
Who should use this billing guide?	12
Who should NOT use this billing guide?	13
Client Eligibility	14
Who can receive substance use disorder (SUD) treatment services under fee-for- service?	14
How do I verify a client's eligibility?	
Behavioral Health Organization (BHO)	
Fully Integrated Managed Care (FIMC)	
Apple Health Foster Care (AHFC)	19
Coverage Table	20
Coverage Limitations	23
Billing for case management or intensive case management	25
Billing	26
What are the general billing requirements?	
What are the recordkeeping requirements specific to substance use disorder treatm	ient
providers?	
What if a client has Medicare coverage?	
How do I bill claims electronically?	
·	
Secure Detoxification	
What is secure detoxification (secure detox)?	
Who is eligible for secure detox?	
Who is eligible to provide and bill for secure detox services?	
What authorization is required?	

Resources Available

Торіс	Contact Information
Becoming a provider or submitting a change of address or ownership	
Finding out about payments, denials, claims processing, or agency managed care organizations	
Electronic billing	See the agency's <u>Billers and Providers</u> web page
Finding agency documents (e.g., Washington Apple Health billing guides and fee schedules)	
Private insurance or third-party liability, other than agency managed care	
	The Division of Behavioral Health and Recovery PO Box 45330 Olympia, WA 98504-5330 360-725-3700
Questions regarding policy or payment rates	or
	Washington State Health Care Authority Medical Assistance Customer Service Center (MACSC) <u>Contact MACSC</u> 1-800-562-3022

Definitions

This section defines terms and abbreviations, including acronyms, used in this billing guide. Refer to <u>Chapter 182-500 WAC</u> for a complete list of definitions for Washington Apple Health.

Agency - The Washington State Health Care Authority.

Agency's designee – Any entity expressly designated by the agency to act on its behalf.

American Indian/Alaska Native (AI/AN) – A person having origins in any of the original peoples of North America, or people who selfidentify as AI/AN when they:

- Apply or re-certify for Medicaid
- Submit a change in Healthplanfinder or through the HCA Medicaid Customer Service Center.

Approved treatment facility - A treatment facility, either public or private, for profit or nonprofit, approved by the agency according to 246-341 WAC and RCW <u>70.96A</u>.

American Society of Addiction Medicine (ASAM) - An international organization of physicians dedicated to improving the treatment of persons with substance use disorders.

ASAM Criteria- A clinical tool used to systematically evaluate the severity and diagnosis of a person's need for treatment along six dimensions, and then use a fixed combination rule to determine which level of care a substance-using person will respond to with the greatest success. ASAM also includes recommended duration of substance use disorder (SUD) treatment services along the continuum. Assessment - The set of activities conducted on behalf of a new patient, for the purpose of determining eligibility, evaluating treatment needs, and making necessary referrals and completing forms. The assessment includes all practices listed in applicable sections of Chapter 246-341 WAC or its successor. For the purpose of determining eligibility for Chemical Dependency Disposition Alternative (CDDA), the set of activities will include completion of all of the following:

- The Adolescent Drug Abuse Diagnosis (ADAD)
- The *Kiddie* version of the Schedule of Affective Disorders and Schizophrenia (K-SADS)
- American Society of Addiction medicine (ASAM) questionnaire forms

Case management - Services provided by a Chemical Dependency Professional (CDP) or CDP Trainee to clients assessed as needing treatment and admitted into treatment. Services are provided to assist clients in gaining access to needed medical, social, educational, and other services. Services include case planning, case consultation and referral, and other support services for the purpose of engaging and retaining or maintaining clients in treatment.

Chemical Dependency Professional (CDP)

- A person certified as a chemical dependency professional by the Washington State Department of Health under Chapter <u>18.205</u> RCW.

Chemical Dependency Professional Trainee

(**CDPT**) - A person certified as a chemical dependency professional trainee by the Washington State Department of Health under Chapter <u>18.205</u> RCW.

Client - A person receiving substance use disorder treatment services from a DBHR-certified agency.

Core provider agreement – An agreement between the agency and eligible providers. The agency reimburses enrolled eligible providers for covered medical services, equipment, and supplies they provide to eligible clients.

Division of Behavioral Health and Recovery Division (DBHR) - The Behavioral Health and Recovery Division (BHR) provides support for mental health, substance use disorder, and problem gambling services. The public mental health programs promote recovery and resiliency and reduces the stigma associated with mental illness. The substance abuse prevention and substance use disorder treatment programs promote strategies that support healthy lifestyles by preventing the misuse of alcohol, tobacco, and other drugs, and support recovery from the disease of substance use disorder. The problem gambling program mitigates the effects of problem gambling on the family and helps families remain economically self-sufficient without requiring assistance from other state programs. DBHR brings operational elements like medical assistance, substance use disorder and mental health into closer working relationships that serve clients more effectively and efficiently than before.

Fee-for-service (FFS) See WAC <u>182-500-</u> <u>0035</u>.

Group therapy - Planned therapeutic or counseling activity conducted by one or more certified CDPs or CDPTs to a group of two or more unrelated individuals. Acupuncture may be included as a group therapy activity if all of the following are met:

- A CDP or CDPT is present during the activity
- The provision of these services is written into the master treatment plan for the client
- The services are documented in the client case file in the progress notes

Individual therapy - A planned therapeutic or counseling activity provided to an eligible client by a certified chemical dependency professional (CDP) or a CDP trainee under the supervision of a CDP. Individual therapy includes treatment provided to a family group consisting of a primary client and one or more significant others, or treatment provided to a couple who are partnered. Individual therapy may be provided to a family group without the primary client present or to a client without the family present.

Institution for mental diseases (IMD) - A hospital, nursing facility, or other institution of more than sixteen beds that is primarily engaged in providing diagnosis, treatment or care of people with mental diseases, including medical attention, nursing care and related services. An IMD may include inpatient chemical dependency facilities of more than sixteen beds which provide residential treatment for alcohol and substance abuse. See WAC 182-500-0050. Maximum allowable - The maximum dollar amount a provider may be reimbursed by the agency for specific services, supplies, or equipment.

Opiate substitution treatment services

(OST) - Treatment services and medication (methadone) for individuals addicted to opiates as described in Chapter 246-341 WAC.

OSTs are bundled services. Services are consistent with all state and federal requirements and good treatment practices. Bundled services must include, as a minimum, all of the following services:

- Physical evaluation upon admission
- Urinalysis testing*
- Medical examination within 14 days of admission and annually thereafter
- Initial treatment plan and treatment plan review one time per month for the first three months and quarterly thereafter
- Vocational rehabilitation services as needed (may be by referral)
- Dose preparation and dose dispensing (Methadone and other treatment drugs)
- Detoxification if and when needed
- Patient case management
- Individual and/or group counseling one time per week for the first three months and monthly thereafter
- One session of family planning; 30 minutes of counseling and education per month for pregnant enrollees
- HIV screening, counseling, and testing referral
- Courtesy dosing

*Urinalysis tests (UAs) are part of the bundled service daily rate. For more information, see the *Drug Testing for Substance Use Disorder* section of the agency's <u>Physician-Related Services/Health</u> <u>Care Professional Services Billing Guide</u>. **Residential Services** - A complete range of services and supports performed in a live-in setting as authorized by DBHR. **Note:** No additional fee will be reimbursed for different types of medication used.

Pregnant and postpartum women (PPW) assessment - Assessment provided to an eligible woman who is pregnant or postpartum. The postpartum period covers the 60 days after delivery and any remainder of the month in which the 60th day falls.

Provider Entry Portal (PEP) - The PEP allows registration and data submission, as defined by the <u>Behavioral Health Data System</u> <u>Data Guide</u>, by non-tribal providers for American Indian/Alaska Native (AI/AN) Medicaid clients not enrolled in managed care.

ProviderOne -The agency's primary provider payment processing system.

ProviderOne Client ID - A system-assigned number that uniquely identifies a single client within the ProviderOne system; the number consists of nine numeric characters followed by "WA".

Secure detoxification (Secure detox) - Care and treatment of a person while the person recovers from the transitory effects of acute or chronic intoxication or withdrawal from alcohol or other drugs. The designated crisis responder (DCR) will determine if a person is "gravely disabled or presenting a likelihood of serious harm to self or others due to a substance use disorder." Treatment provided is for people who meet Involuntary Treatment Act (ITA) criteria due to a substance use disorder (Chapter <u>71.05</u> RCW).

Substance use disorder - A problematic pattern of substance abuse leading to clinically significant impairment or distress, ranging in severity from mild, moderate, or severe. **Substance use disorder treatment** - Medical and rehabilitative social services provided to an eligible client designed to mitigate or reverse the effects of substance use disorder and restore normal physical and psychological functioning. Drug addiction or drug abuse treatment is characterized by a combination of drug and alcohol education sessions, individual therapy, group therapy, and related activities provided to detoxified clients and their families.

Urinalysis - Analysis of a client's urine sample for the presence of alcohol or controlled substances by a licensed laboratory or a provider who is exempted from licensure by the Department of Health.

Withdrawal management - Care and treatment of a person while the person recovers from the transitory effects of acute or chronic intoxication or withdrawal from alcohol or other drugs.

- Acute Inpatient program that is medically monitored by nurses with oncall physicians available 24/7 for consultation. They have "standing orders" and available medications to help with withdrawal symptoms.
- Sub-Acute Residential program that is clinically managed with limited medical coverage by staff and counselors who monitor patients. Generally, any treatment medications are self-administered.

Substance Use Disorder Treatment

Who should use this billing guide?

- Department of Health (DOH)-certified substance use disorder (SUD) providers, including outpatient programs and non-institutional for mental disease (non-IMD) residential programs registered in the Provider Entry Portal (PEP) (see the <u>Contractor and provider</u> resources webpage for information about registering through PEP)
- Providers who have registered through the PEP and are delivering Medicaid fee-forservice (FFS) substance use disorder services to clients who are not enrolled in a behavioral health organization (BHO), fully integrated managed care (FIMC), or behavioral health services only (BHSO)
- Indian health care providers rendering services for Apple Health clients and billing FFS regardless of BHO/FIMC/managed care organization (MCO) enrollment
- Federally qualified health centers (FQHCs) rendering services for encounter-eligible Apple Health clients and billing FFS regardless of BHO/FIMC/MCO enrollment

To correctly bill, providers must use this billing guide, the appropriate fee schedule(s), and their Core Provider Agreement with the Health Care Authority.

If there is a discrepancy between a provider's contract stipulations and this billing guide, the provider's contract stipulations take precedence.

Who should NOT use this billing guide?

The following providers should NOT use this guide:

- Providers delivering substance use disorder (SUD) services to a client using BHO coverage (See the <u>BHO Contacts</u> sheet)
- IMD residential programs with over 16 beds (<u>Contact DBHR</u> for information about the billing process). Psychiatric residential treatment facilities (PRTFs) are not considered IMDs according to the Centers for Medicare and Medicaid Services (CMS), and SUD claims must be billed the same as a non-IMD facility
- Providers billing for a client that has coverage through one of the managed care organizations (MCOs) listed in <u>Step 3. Verify the client's managed care information</u>

Note: A person who is not eligible for or covered by Medicaid may receive some services through Beacon Health Options, within its available funding.

Client Eligibility

Who can receive substance use disorder (SUD) treatment services under fee-for-service?

To receive fee-for-service (FFS) substance use disorder (SUD) treatment services, a client must meet all of the following:

- Not be enrolled in a behavioral health organization (BHO), fully integrated managed care (FIMC), or behavioral health services only (BHSO) that is listed in <u>Step 3. Verify</u> the client's managed care information
- Have Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) diagnosis of substance use disorder, mild, moderate, or severe
- Meet medical necessity criteria as stated in the American Society of Addiction Medicine (ASAM)
- Be age 10 or older (treatment for clients under age 10 must be authorized by a DBHR Behavioral Health Administrator).

Note: Federally Qualified Health Centers (FQHCs) and Indian health care providers rendering outpatient services and billing FFS will use this billing guide regardless of a client's BHO, FIMC, or BHSO enrollment. See <u>How can I verify a client's eligibility</u>? to determine BHO, FIMC, or BHSO enrollment.

How do I verify a client's eligibility?

Check the client's Services Card or follow the four-step process below to verify that a client has Apple Health coverage for the date of service and that the client's benefit package covers the applicable service. This helps prevent delivering a service the agency will not pay for.

Note: If a client's benefit package indicates "Suspended – Inpatient Hospital Services Only" for the date of service, it means that the Jail Booking and Reporting System shows that the client was incarcerated for the date of service. Apple Health covers inpatient hospital services only for the suspension dates. All other services during the suspension timeframe are covered by the jail or state hospital. For more information or instructions on how to make corrections if the client was not incarcerated, see the agency's <u>Medicaid suspension webpage</u>.

Insurance Type Code	Recipient Aid Category (RAC)	Benefit Service Package	Eligibility Start Date	Eligibility End Date	ACES Coverage Group
A.V.	A.A.	47	۸Ÿ		A.V.
MC: Medicaid	8500	SBP - Institutionalized Dates	04/19/2018	12/31/2999	
MC: Medicaid	1201	ABP	04/21/2018	12/31/2909	N05
MC: Medicaid	1201	Suspended - Inpatient Hospital Services Only	04/20/2018	04/20/2018	N05
MC: Medicaid	1201	ABP	06/01/2016	04/19/2018	N05

Is the client enrolled in an agency-contracted managed care organization (MCO), in a behavioral health organization (BHO), or is the client receiving services through fee-for-service (FFS) Apple Health?

Verifying eligibility is a four-step process:

Step 1. Verify the patient's eligibility for Apple Health. For detailed instructions on verifying a patient's eligibility for Apple Health, see the *Client Eligibility, Benefit Packages, and Coverage Limits* section in the agency's ProviderOne Billing and Resource Guide.

Note: A client's coverage can change at any time, so check eligibility at each visit.

If the patient is eligible for Apple Health, proceed to **Step 3**. If the patient is **not** eligible, see the note box in **Step 2**.

Step 2. Verify service coverage under the Apple Health client's benefit package. To determine if the requested service is a covered benefit under the Apple Health client's benefit package, see the agency's <u>Program Benefit Packages and Scope of Services</u> web page.

Note: Patients who are not Washington Apple Health clients may submit an application for health care coverage in one of the following ways:

- 1. By visiting the Washington Healthplanfinder's website at: www.wahealthplanfinder.org
- 2. By calling the Customer Support Center toll-free at: 855-WAFINDER (855-923-4633) or 855-627-9604 (TTY)
- By mailing the application to: Washington Healthplanfinder PO Box 946 Olympia, WA 98507

In-person application assistance is also available. To get information about inperson application assistance available in their area, people may visit <u>www.wahealthplanfinder.org</u> or call the Customer Support Center.

Step 3. Verify the client's managed care information. If the client has one of the following listed under the *Managed Care Information* section, then that client has managed care (BHO, FIMC, or BHSO) for SUD services (see exception below):

AMG Behavioral Health Services Only
AMG Fully Integrated Managed Care
CCW Behavioral Health Services Only
CCW Fully Integrated Managed Care
CHPW Behavioral Health Services Only
CHPW Fully Integrated Managed Care
Great Rivers Behavioral Health Organization
Greater Columbia Behavioral Health
King County Behavioral Health Organization
MHC Behavioral Health Services Only
MHC Fully Integrated Managed Care
North Sound Behavioral Health Org
Optum Pierce BHO
Salish Behavior Health Organization
Spokane Behavioral Health Organization
Thurston-Mason Behavioral Health Organizations

Exception: FQHCs and Indian health care providers rendering outpatient services and who bill FFS must use the instructions in this billing guide regardless of a client's BHO, FIMC, or BHSO enrollment.

The following example shows a client who was enrolled with North Sound Behavioral Health Organization from January 1, 2017, through August 31, 2017:

						1	
Insurance Type Code	PCCM Code	Plan/PCCM Name	Plan/PCCM ID	Plan/PCCM Phone Number	PCP Clinic Name	Start Date	End Date
- ·			* *	A V.			
HM: Health Maintenance	MC:	MHC Healthy Options	105010201	(800) 869-7165		07/01/2012	12/21/2000
Organization	Capitated	wine rieauty options	103010201	(000) 003-1100		01/01/2012	12/51/255
HM: Health Maintenance	MC:	North Sound Behavioral Health	105020902	(360) 416-7013		01/01/2017	00/04/004
Organization	Capitated	Org	105020902	(300) 410-7013		01/01/2017	00/31/201

- ✓ SUD services provided for dates of service from January 1, 2017, through June 30, 2017, are addressed in the SUD Billing Guide that was in effect for those dates.
- ✓ SUD services provided for dates of service from July 1, 2017 through August 31, 2017, are billed to North Sound Behavioral Health Organization.
- ✓ SUD services provided for dates of service on and after September 1, 2017, are billed to the agency.
- ✓ NOTE: MHC Healthy Options is not included in the list of managed care programs that cover SUD services.

Behavioral Health Organization (BHO)

Effective July 1, 2018, the Health Care Authority manages the contracts for behavioral health services (mental health and substance use disorder) for eight of the Regional Service Areas (RSAs) in the state. The remaining regions have <u>fully integrated managed care (FIMC)</u>.

See the agency's <u>Mental Health Services Billing Guide</u> for details.

Fully Integrated Managed Care (FIMC)

For clients who live in an FIMC region, all physical health services, mental health services, and drug and alcohol treatment are covered and coordinated by the client's agency-contracted MCO. The BHO will not provide behavioral health services in these counties.

Clients living in an FIMC region will enroll with an MCO of their choice that is available in that region. If the client does not choose an MCO, the client will be automatically enrolled into one of the available MCOs, unless the client is American Indian/Alaska Native (AI/AN). Clients currently enrolled in one of the available MCOs in their region may keep their enrollment when the behavioral health services are added.

Effective July 1, 2017, American Indian/Alaska Native (AI/AN) clients living in an FIMC region of Washington may choose to enroll in one of the agencycontracted MCOs available in that region or they may choose to receive all these services through Apple Health FFS. If they do not choose an MCO, they will be automatically enrolled into Apple Health FFS for all their health care services, including comprehensive behavioral health services. See the agency's <u>American</u> <u>Indian/Alaska Native webpage</u>.

For more information about the services available under the FFS program, see the agency's <u>Mental Health Services Billing Guide</u> and the <u>Substance Use Disorder</u> <u>Billing Guide</u>.

For full details on FIMC, see the agency's Changes to Apple Health managed care webpage.

FIMC Regions

Clients who reside in either of the following two FIMC regions and who are eligible for managed care enrollment must choose an available MCO in their region. Specific details, including information about mental health crisis services, can be found on the agency's <u>Apple Health</u> managed care webpage.

North Central Region – Douglas, Chelan and Grant Counties Effective January 1, 2018, the agency implemented the second FIMC region known as the North Central Region, which includes Douglas, Chelan, and Grant Counties.

Southwest Washington Region – Clark and Skamania Counties

Effective April 1, 2016, the agency implemented the first FIMC region known as the Southwest Washington Region, which includes Clark and Skamania Counties. Clients eligible for managed care enrollment choose to enroll in one of two available MCOs in this region.

Apple Health Foster Care (AHFC)

Coordinated Care of Washington (CCW) provides all physical health care (medical) benefits, lower-intensity outpatient mental health benefits and care coordination for all Washington State foster care enrollees through a single, statewide managed care plan known as Apple Health Core Connections (AHCC).

Clients under this program are:

- Under the age of 21 who are in foster care (out of home placement)
- Under the age of 21 who are receiving adoption support
- Age 18-21 years old in extended foster care
- Age 18 to 26 years old who aged out of foster care on or after their 18th birthday (alumni)

These clients are identified in ProviderOne as "Coordinated Care Healthy Options Foster Care."

See the agency's <u>Apple Health managed care page</u>, Apple Health Foster Care for further details.

Coverage Table

The agency covers the following substance use disorder (SUD) services with the <u>coverage</u> <u>limitations</u> listed in this guide.

Only the following combinations of procedure code, modifier, and taxonomy may be reimbursed for the SUD program.

Procedure Code	Modifier	Short Description	Service	Taxonomy
H0001	HD	Alcohol and/or drug assess	Substance use disorder assessment, Pregnant and Parenting Women (PPW)	261QR0405X
H0001	HF	Alcohol and/or drug assess	Substance use disorder assessment	261QR0405X
H0004	HF	Alcohol and/or drug services	Individual therapy, without family present, per 15 minutes	261QR0405X
H0010	НА	Alcohol and/or drug services	Youth sub-acute withdrawal management	3245S0500X
H0010	HF	Alcohol and/or drug services	Adult sub-acute withdrawal management	324500000X
H0011	НА	Alcohol and/or drug services	Youth acute withdrawal management	3245S0500X
H0011	HF	Alcohol and/or drug services	Adult acute withdrawal management	324500000X

Modifier	Description
HA	Child/Adolescent Program
HB	Adult Program, non-geriatric
HD	Pregnant and Parenting Women (PPW)
HF	Substance Abuse Program
HV	Funded State Addiction Agency (Non-IMD Program)
	CPT® codes and descriptions only are copyright 2016 American Medical Association.

Procedure Code	Modifier	Short Description	Service	Taxonomy
H0018	НА	Alcohol and/or drug services	Youth recovery house	3245S0500X
H0018	HF	Alcohol and/or drug services	Adult recovery house	324500000X
H0018	HV	Alcohol and/or drug services	Adult intensive inpatient residential, w/o room and board, per diem	324500000X
H0019	НА	Alcohol and/or drug services	Youth intensive inpatient residential, w/o room and board, per diem	3245S0500X
H0019	HB	Alcohol and/or drug services	Residential treatment, Pregnant and Parenting Women (PPW) w/Children, w/o room and board, per diem	324500000X
H0019	HD	Alcohol and/or drug services	Residential treatment, Pregnant and Parenting Women (PPW) w/o Children, w/o room and board, per diem	324500000X
H0019	TG	Alcohol and/or drug services	Residential treatment, long term recovery	324500000X
H0020	HF	Alcohol and/or drug services	Opiate Substitution Treatment, methadone administration	261QM2800X
H2036	НА	A/d tx program, per diem	Youth room and board*	3245S0500X

Modifier	Description
HA	Child/Adolescent Program
HB	Adult Program, non-geriatric
HD	Pregnant and Parenting Women (PPW)
HF	Substance Abuse Program
HV	Funded State Addiction Agency (Non-IMD Program)
r	CPT® codes and descriptions only are copyright 2016 American Medical Association.

Procedure Code	Modifier	Short Description	Service	Taxonomy
H2036	HD	A/d tx program, per diem	PPW room and board*	324500000X
H2036	HF	A/d tx program, per diem	Adult room and board*	324500000X
T1017	HF	Targeted case management	Case management, each 15 minutes	251B00000X
96153	HF	Intervene hlth/behave group	Group therapy	261QR0405X
96154	HF	Interv hlth/behav fam w/pt	Family therapy with enrollee present	261QR0405X
96155	HF	Interv hlth/behav fam no pt	Family therapy without enrollee present	261QR0405X

*Room and board is paid for with state-only funds.

Modifier	Description
HA	Child/Adolescent Program
HB	Adult Program, non-geriatric
HD	Pregnant and Parenting Women (PPW)
HF	Substance Abuse Program
HV	Funded State Addiction Agency (Non-IMD Program)
CPT [®] codes and descriptions only are copyright 2016 American Medical Association.	

Coverage Limitations

Covered substance use disorder (SUD) treatment services are subject to the following limitations.

SERVICE	LIMITATION
Acute Withdrawal Management	Covered once per day, per client
Case Management	 One unit equals 15 minutes Must be provided by a certified Chemical Dependency Professional (CDP) or Chemical Dependency Professional Trainee CDPT Providers cannot bill for the following activities: Outreach Time spent reviewing a certified CDP Trainee's file notes Internal staffing Writing treatment compliance notes and progress reports to the court Interactions with probation officers Court reporting Claims for group therapy may be made only for those eligible clients
	 One unit equals 15 minutes One unit equals 15 minutes Note: When family members attend a group therapy session either in lieu of or along with the primary client, the session may be claimed only once regardless of the number of family members present. Providers must bill group therapy services under the client's ProviderOne identification number.
Individual Therapy	 Individual therapy is covered only when provided for a minimum of 15 minutes One unit equals 15 minutes. Note: When family members attend an individual session either in lieu of, or along with, the primary client, the session may be claimed only once, regardless of the number of family members present.

SERVICE	LIMITATION
Opiate Substitution Treatment	• Covered once per day while a client is in treatment
Substance Use Disorder	• Covered once per treatment episode for each new and returning client
Assessment	Note: Providers must not bill updates to assessments or treatment plans as separate assessments.
Sub-Acute Withdrawal Management	Covered once per day, per client
Urinalysis (UA) Drug Testing	• UA drug testing is not a separately payable service and is bundled into the treatment payment, except when provided to methadone clients and PPW clients. For these clients only, DBHR-contracted laboratories perform and are paid separately for UA drug testing.

Billing for case management or intensive case management

Providers must not bill for case management or intensive case management if the client is:

- Pregnant and receiving Maternity Support Services (MSS) or Infant Case Management (ICM) services under the agency's First Steps Program.
- Receiving Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) case management services through the Department of Health (DOH).
- A youth on parole in a non-residential setting and under Rehabilitation Administration (RA) supervision.
- A youth in foster care through the Children's Administration (CA).
- Receiving case management services through any other funding source from any other agency system (i.e., a person enrolled in Mental Health with a Primary Health Provider).

Billing for case management for the above situations is prohibited because federal financial participation is being collected by the agency or agency designee, DOH, RA, or the Division of Behavioral Health and Recovery (DBHR) for these clients.

Billing

All claims must be submitted electronically to the agency, except under limited circumstances. For more information about this policy change, see <u>Paperless Billing at HCA</u>. For providers approved to bill paper claims, see the agency's <u>Paper Claim Billing Resource</u>.

What are the general billing requirements?

With the exception of Indian health care providers and federally qualified health centers (FQHCs) rendering outpatient substance use disorder (SUD) services, all providers must register through the DSHS Provider Entry Portal (PEP) on the <u>Contractor and provider resources</u> webpage in order to render SUD services to Apple Health clients.

Providers must follow the agency's <u>ProviderOne Billing and Resource Guide</u>. These billing requirements include:

- What time limits exist for submitting and resubmitting claims and adjustments.
- When providers may bill a client.
- How to bill for services provided to primary care case management (PCCM) clients.
- How to bill for clients eligible for both Medicare and Medicaid.
- How to handle third-party liability claims.
- What standards to use for record keeping.

What are the recordkeeping requirements specific to substance use disorder treatment providers?

- A substance use disorder assessment and history of involvement with alcohol or other drugs
- Initial and updated individual treatment plans, including results of the initial assessment and periodic reviews
- Date, duration, and content of counseling and other treatment sessions
- Progress notes as events occur, and treatment plan reviews as specified under each treatment service or Chapter 246-341 WAC

- Release of information form signed by the client to share information with the agency
- A copy of the continuing care plan signed and dated by the Chemical Dependency Professional (CDP) and the client
- The discharge summary
- Fee-for-service (FFS) providers must document services provided to American Indian/Alaska Native (AI/AN) clients. Services must be documented in the Behavioral Health Data System through PEP.

What if a client has Medicare coverage?

Medicare does not pay for substance use disorder (SUD) treatment services provided in freestanding outpatient treatment centers unless the services are actually **provided** by a physician (not just **overseen** by a physician). Do not bill Medicare prior to billing the agency or agency designee for SUD treatment services. Outpatient and residential SUD services rendered by CDPs or Chemical Dependency Professional Trainees (CDPTs) may be billed directly to the agency without attaching a Medicare explanation of benefits.

Where can I find substance use disorder fee schedules?

See the agency's Substance Use Disorder Fee Schedule.

How do I bill claims electronically?

Instructions on how to bill Direct Data Entry (DDE) claims can be found on the agency's <u>Billers</u> and <u>Providers</u> web page, under <u>Webinars</u>.

For information about billing Health Insurance Portability and Accountability Act (HIPAA) Electronic Data Interchange (EDI) claims, see the ProviderOne 5010 companion guides on the <u>HIPAA Electronic Data Interchange (EDI)</u> web page.

The following claim instructions relate to billing Substance Use Disorder program services on a professional claim form:

Name	Entry
Place of Service	The following is the only appropriate code(s) for Washington State Medicaid:
	State Medicald:
	Code
	Number To Be Used For
	05 Indian Health Service free-standing facility
	07 Tribal 638 free-standing facility
	50 Federally Qualified Health Center (FQHC)
	55 Residential Substance Use Disorder Treatment Facility
	57 Non-residential Substance Use Disorder Treatment Facility
	Note: Place of Service codes have been expanded to include all places of service related to providing SUD treatment services.
Rendering	Do not add individual servicing NPIs to SUD claims. SUD claims
provider	are billed at the clinic level only.

Diagnosis Code	Substance Use Disorder Diagnosis Criteria
Limited to assessm	nent and outpatient treatment services.
See the table below for the appropriate ICD code. A diagnosis code is required on each line billed.	Clients must have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) diagnosis of mild, moderate, or severe; and Meet medical necessity criteria as stated in American Society of Addiction Medicine (ASAM).

What are the ICD-10 diagnosis code requirements?

Primary diagnoses listed in the following table are the only covered diagnoses for SUD claims. Italicized descriptions are the ICD-10-CM descriptions for the ICD-10-CM code. Descriptions that are not in italics are from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

ICD-10-CM Code	Description
F10.10	Alcohol abuse, uncomplicated
	Alcohol use disorder, Mild
F10.129	Alcohol abuse with intoxication, unspecified
	Alcohol intoxication, With mild use disorder
F10.20	Alcohol dependence, uncomplicated
	Alcohol use disorder, Moderate
	Alcohol use disorder, Severe
F10.229	Alcohol dependence with intoxication, unspecified
	Alcohol intoxication, With moderate or severe use disorder
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified
	Alcohol-induced psychotic disorder, With moderate or severe use disorder
F11.10	Opioid abuse, uncomplicated
	Opioid use disorder, Mild
F11.129	Opioid abuse with intoxication, unspecified
	Opioid intoxication, With perceptual disturbances, With mild use disorder
F11.20	Opioid dependence, uncomplicated
	Opioid use disorder, Moderate
	Opioid use disorder, Severe
F11.221	Opioid dependence with intoxication delirium
	Opioid intoxication delirium, With moderate or severe use disorder
F11.222	Opioid dependence with intoxication with perceptual disturbance
	Opioid intoxication, with perceptual disturbances, With moderate or
	severe use disorder
F11.229	Opioid dependence with intoxication, unspecified
	Opioid intoxication, Without perceptual disturbances, With moderate or
	severe use disorder
F11.23	Opioid dependence with withdrawal
	Opioid withdrawal
	Opioid withdrawal delirium
F11.24	Opioid dependence with opioid-induced mood disorder
	Opioid-induced depressive disorder, With moderate or severe use disorder
F11.281	Opioid dependence with opioid-induced sexual dysfunction
	Opioid-induced sexual dysfunction, With moderate or severe use disorder
F11.282	Opioid dependence with opioid-induced sleep disorder
	Opioid-induced sleep disorder, With moderate or severe use disorder

ICD-10-CM Code	Description
F11.288	Opioid dependence with other opioid-induced disorder
	Opioid-induced anxiety disorder, With moderate or severe use disorder
F12.10	Cannabis abuse, uncomplicated
	Cannabis use disorder, Mild
F12.129	Cannabis abuse with intoxication, unspecified
	Cannabis intoxication, Without perceptual disturbances, With mild use
	disorder
F12.20	Cannabis dependence, uncomplicated
	Cannabis use disorder, Moderate
	Cannabis use disorder, Severe
F12.221	Cannabis dependence with intoxication delirium
	Cannabis intoxication delirium, With moderate or severe use disorder
F12.229	Cannabis dependence with intoxication, unspecified
	Cannabis intoxication, With perceptual disturbances, With moderate or
	severe use disorder
F12.259	Cannabis dependence with psychotic disorder, unspecified
	Cannabis-induced psychotic disorder, With moderate or severe use
	disorder
F12.280	Cannabis dependence with cannabis-induced anxiety disorder
	Cannabis-induced anxiety disorder, With moderate or severe use disorder
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated
	Sedative, hypnotic, or anxiolytic use disorder, Mild
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified
	Sedative, hypnotic, or anxiolytic intoxication, With mild use disorder
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated
	Sedative, hypnotic, or anxiolytic use disorder, Moderate
	Sedative, hypnotic, or anxiolytic use disorder, Severe
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium
	Sedative, hypnotic, or anxiolytic intoxication delirium, With moderate or
	severe use disorder
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified
	Sedative, hypnotic, or anxiolytic intoxication, With moderate or severe
	use disorder
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium
	Sedative, hypnotic, or anxiolytic withdrawal delirium
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with
	perceptual disturbance
	Sedative, hypnotic, or anxiolytic withdrawal, With perceptual
	disturbances
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified
	Sedative, hypnotic, or anxiolytic withdrawal, Without perceptual
	disturbances

ICD-10-CM Code	Description
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or
	anxiolytic-induced mood disorder
	Sedative-, hypnotic, or anxiolytic-induced depressive disorder, With
	moderate or severe use disorder
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or
	anxiolytic-induced psychotic disorder, unspecified
	Sedative-, hypnotic-, or anxiolytic-induced psychotic disorder, With
	moderate or severe use disorder
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or
	anxiolytic-induced persisting dementia
	Sedative-, hypnotic-, or anxiolytic-induced major neurocognitive disorder,
	With moderate or severe use disorder
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or
	anxiolytic-induced anxiety disorder
	Sedative-, hypnotic-, or anxiolytic-induced anxiety disorder, With
	moderate or severe use disorder
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or
	anxiolytic-induced sexual dysfunction
	Sedative-, hypnotic-, or anxiolytic-induced sexual dysfunction, With
	moderate or severe use disorder
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or
	anxiolytic-induced sleep disorder
	Sedative-, hypnotic-, or anxiolytic-induced sleep disorder, With moderate
	or severe use disorder
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic
	or anxiolytic-induced disorder
	Sedative-, hypnotic-, or anxiolytic-induced mild neurocognitive disorder,
	With moderate or severe use disorder
F14.10	Cocaine abuse, uncomplicated
	Cocaine use disorder, Mild
F14.122	Cocaine abuse with intoxication with perceptual disturbance
	Cocaine intoxication, With perceptual disturbances, With mild use
	disorder
F14.129	Cocaine abuse with intoxication, unspecified
	Cocaine intoxication, Without perceptual disturbances, With mild use
T ((A)	disorder
F14.20	Cocaine dependence, uncomplicated
	Cocaine use disorder, Moderate
E14 001	Cocaine use disorder, Severe
F14.221	Cocaine dependence with intoxication delirium
F14 000	Cocaine intoxication delirium, With moderate or severe use disorder
F14.222	Cocaine dependence with intoxication with perceptual disturbance
	Cocaine intoxication, With perceptual disturbances, With moderate or
	severe use disorder

ICD-10-CM Code	Description
F14.229	Cocaine dependence with intoxication, unspecified
	Cocaine intoxication, Without perceptual disturbances, With moderate or
	severe use disorder
F14.23	Cocaine dependence with withdrawal
	Cocaine withdrawal
F14.24	Cocaine dependence with cocaine-induced mood disorder
	Cocaine-induced bipolar and related disorder, With moderate or severe
	use disorder
	Cocaine-induced depressive disorder, With moderate or severe use
	disorder
F14.259	<i>Cocaine dependence with cocaine-induced psychotic disorder, unspecified</i>
	Cocaine-induced psychotic disorder, With moderate or severe use disorder
F14.280	Cocaine dependence with cocaine-induced anxiety disorder
	Cocaine-induced anxiety disorder, With moderate or severe use disorder
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction
	Cocaine-induced sexual dysfunction, With moderate or severe use
	disorder
F14.282	Cocaine dependence with cocaine-induced sleep disorder
	Cocaine-induced sleep disorder, With moderate or severe use disorder
F14.288	Cocaine dependence with other cocaine-induced disorder
	Cocaine-induced obsessive-compulsive and related disorder, With
	moderate or severe use disorder
F15.10	Other stimulant abuse, uncomplicated
	Amphetamine-type substance use disorder, Mild
	Other or unspecified stimulant use disorder, Mild
F15.122	Other stimulant abuse with intoxication with perceptual disturbance
	Amphetamine or other stimulant intoxication, With perceptual
	disturbances, With mild use disorder
F15.129	Other stimulant abuse with intoxication, unspecified
	Amphetamine or other stimulant intoxication, Without perceptual
	disturbances, With mild use disorder
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder,
	unspecified
	Amphetamine (or other stimulant)-induced psychotic disorder, With mild
	use disorder
F15.20	Other stimulant dependence, uncomplicated
	Amphetamine-type substance use disorder, Moderate
	Amphetamine-type substance use disorder, Severe
	Other or unspecified stimulant use disorder, Moderate
	Other or unspecified stimulant use disorder, Severe
F15.221	Other stimulant dependence with intoxication delirium
	Amphetamine (or other stimulant) intoxication delirium, With moderate or
	severe use disorder

ICD-10-CM Code	Description
F15.222	Other stimulant dependence with intoxication with perceptual disturbance
	Amphetamine or other stimulant intoxication, With perceptual
	disturbances, With moderate or severe use disorder
F15.229	Other stimulant dependence with intoxication, unspecified
	Amphetamine or other stimulant intoxication, Without perceptual
	disturbances, With moderate or severe use disorder
F15.23	Other stimulant dependence with withdrawal
	Amphetamine or other stimulant withdrawal
F15.24	Other stimulant dependence with stimulant-induced mood disorder
	Amphetamine (or other stimulant)-induced bipolar and related disorder,
	With moderate or severe use disorder
	Amphetamine (or other stimulant)-induced depressive disorder, With
	moderate or severe use disorder
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder,
	unspecified
	Amphetamine (or other stimulant)-induced psychotic disorder, With
	moderate or severe use disorder
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder
	Caffeine-induced anxiety disorder, With moderate or severe use disorder
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction
	Amphetamine (or other stimulant)-induced sexual dysfunction, With
	moderate or severe use disorder
F15.282	Other stimulant dependence with stimulant-induced sleep disorder
	Amphetamine (or other stimulant)-induced sleep disorder, With moderate
	or severe use disorder
	Caffeine-induced sleep disorder, With moderate or severe use disorder
F15.288	Other stimulant dependence with other stimulant-induced disorder
	Amphetamine (or other stimulant)-induced obsessive-compulsive and
	related disorder, With moderate or severe use disorder
F16.10	Hallucinogen abuse, uncomplicated
	Other hallucinogen use disorder, Mild
	Phencyclidine use disorder, Mild
F16.129	Hallucinogen abuse with intoxication, unspecified
	Other hallucinogen intoxication, With mild use disorder
	Phencyclidine intoxication, With mild use disorder
F16.20	Hallucinogen dependence, uncomplicated
	Other hallucinogen use disorder, Moderate
	Other hallucinogen use disorder, Severe
	Phencyclidine use disorder, Moderate
F1 < 001	Phencyclidine use disorder, Severe
F16.221	Hallucinogen dependence with intoxication with delirium
	Other hallucinogen intoxication delirium, With moderate or severe use
	disorder
	Phencyclidine intoxication delirium, With moderate or severe use disorder

Other hallucinogen intoxication, With moderate or severe use disorder Phencyclidine intoxication, With moderate or severe use disorder Other hallucinogen-induced bipolar and related disorder, With moderate or severe use disorder Other hallucinogen-induced depressive disorder, With moderate or severe use disorder F16.24 Hallucinogen-induced depressive disorder, With moderate or severe use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant use disorder, Mild F18.10 Inhalant abuse, uncomplicated Inhalant-induced psychotic disorder, With mild use disorder F18.10 Inhalant abuse with inhalant-induced anxiety disorder F18.10 Inhalant abuse with inhalant-induced anxiety disorder F18.10 Inhalant abuse with inhalant-induced anxiety disorder F18.180 Inhalant abuse with inhalant-induced anxiety disorder F18.180 Inhalant abuse with inhalant-induced anxiety disorder	ICD-10-CM Code	Description
Phencyclidine intoxication, With moderate or severe use disorder F16.24 Hallucinogen dependence with hallucinogen-induced mood disorder Other hallucinogen-induced bipolar and related disorder, With moderate or severe use disorder Other hallucinogen-induced depressive disorder, With moderate or severe use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant Inhalant use disorder, Mild F18.10 Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant induced anxiety disorder, With mild use disorder Inhalant induced anxiety disorder, With mild use disorder F18.10 Inhalant abuse with inhalant-induced disorder Inhalant F18.110 Inhalant abuse with inhalant-induced d	F16.229	Hallucinogen dependence with intoxication, unspecified
F16.24 Hallucinogen dependence with hallucinogen-induced mood disorder Other hallucinogen-induced bipolar and related disorder, With moderate or severe use disorder Other hallucinogen-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder Other hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phalant abuse, uncomplicated Inhalant abuse, with inhalant-induced psychotic disorder Inhalant abuse with inhalant-induced anxiety disorder F18.10 Inhalant abuse with inhalant-induced anxiety disorder F18.18 Inhalant abuse with inhalant-induced anxiety disorder F18.18 Inhalant abuse with inhalant-induced anxiety disorder F18.20 Inhalant abuse with oth		Other hallucinogen intoxication, With moderate or severe use disorder
Other hallucinogen-induced bipolar and related disorder, With moderate or severe use disorder Other hallucinogen-induced depressive disorder, With moderate or severe use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen dependence with hallucinogen-induced psychotic disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen dependence with hallucinogen-induced anxiety disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder F18.10 Inhalant abuse, uncomplicated Inhalant use disorder, Mild F18.10 Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant induced anxiety disorder, With mild use disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.20 Inhalant abuse with other inhalant-induced disorder F18.21 Inhalant dependence with intoxication delirium Inhalant induced mild neurocognitive disorder, With mild use disorder F18.221 Inhalant dependence with intoxication delirium Inhalant use disorder, Severe F18.229 Inhalant de		Phencyclidine intoxication, With moderate or severe use disorder
or severe use disorder Other hallucinogen-induced depressive disorder, With moderate or severe use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen dependence with induced psychotic disorder, with moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant induced psychotic disorder, unspecified Inhalant abuse with inhalant-induced anxiety disorder Inhalant induced anxiety disorder, With mild use disorder F18.180 Inhalant abuse with other inhalant-induced disorder Inhalant abuse with inhalant-induced anxiety disorder, With mild use disorder F18.188 Inhalant dependence, uncomplicated Inhalant dependence, uncomplicated	F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder
or severe use disorder Other hallucinogen-induced depressive disorder, With moderate or severe use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen dependence with induced psychotic disorder, with moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant induced psychotic disorder, unspecified Inhalant abuse with inhalant-induced anxiety disorder Inhalant induced anxiety disorder, With mild use disorder F18.180 Inhalant abuse with other inhalant-induced disorder Inhalant abuse with inhalant-induced anxiety disorder, With mild use disorder F18.188 Inhalant dependence, uncomplicated Inhalant dependence, uncomplicated		Other hallucinogen-induced bipolar and related disorder, With moderate
use disorder Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant abuse, uncomplicated Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder Inhalant-induced anxiety disorder F18.180 Inhalant-induced anxiety disorder, With mild use disorder F18.180 Inhalant-induced anxiety disorder, With mild use disorder F18.20 Inhalant abuse with inhalant-induced disorder Inhalant use disorder, Moderate Inhalant use disorder, Moderate Inhalant use disorder, Moderate Inhalant intoxication delirium Inhalant dependence w		
Phencyclidine-induced depressive disorder, With moderate or severe use disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant use disorder, Mild F18.159 Inhalant abuse with inhalant-induced psychotic disorder Inhalant abuse with inhalant-induced anxiety disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.20 Inhalant dependence, uncomplicated Inhalant use disorder, Severe F18.21 Inhalant dependence with intoxication delirium Inhalant use disorder, Severe F18.229 Inhalant dependence with intoxication delirium Inhalant intoxication, With moderate or severe use disorder F18.24 Inhalant dependence with inhalant-induced mood disorder Inhalant intoxicati		Other hallucinogen-induced depressive disorder, With moderate or severe
disorder F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant use disorder, Mild F18.159 Inhalant abuse with inhalant-induced psychotic disorder Inhalant-induced psychotic disorder, With mild use disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.20 Inhalant dependence, uncomplicated Inhalant use disorder, Severe F18.21 Inhalant dependence with intoxication delirium Inhalant use disorder, Severe F18.229 Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorder F18.24 Inhalant dependence with inhalant-induced mood disorder F18.259 Inhalant dependence with inhalant-induced mood disorder, Inhalant intoxication		use disorder
F16.259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant use disorder, Mild F18.159 Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorder F18.180 Inhalant abuse with inhalant-induced anxiety disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.181 Inhalant dependence, uncomplicated Inhalant use disorder, Moderate F18.20 Inhalant dependence with intoxication delirium Inhalant use disorder, Severe F18.221 Inhalant dependence with intoxication delirium Inhalant intoxication, With moderate or severe use disorder F18.24 Inhalant dependence with inhalant-induced mood disorder F18.259 Inhalant dependence with inhalant-induced psychotic disorder, Inhalant		Phencyclidine-induced depressive disorder, With moderate or severe use
unspecified Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant use disorder, Mild F18.19 Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant abuse with inhalant-induced anxiety disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.180 Inhalant abuse with other inhalant-induced disorder F18.180 Inhalant use disorder, Mild use disorder F18.20 Inhalant abuse with other inhalant-induced disorder F18.20 Inhalant use disorder, Moderate Inhalant use disorder, Severe Inhalant use disorder, Severe F18.221 Inhalant dependence with intoxication delirium Inhalant intoxication, With moderate or severe use disorder F18.229 Inhalant intoxication, With moderate or severe use disorder F18.24 Inhalant intoxication, With moderate or severe use disorder F18.259		disorder
Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder Phencyclidine-induced psychotic disorder, With moderate or severe use disorder F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder Inhalant abuse, uncomplicated Inhalant abuse, uncomplicated Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorder F18.180 Inhalant abuse with inhalant-induced anxiety disorder Inhalant abuse with inhalant-induced anxiety disorder Inhalant abuse with inhalant-induced disorder F18.180 Inhalant abuse with inhalant-induced disorder Inhalant abuse with inhalant-induced disorder Inhalant abuse with inhalant-induced disorder Inhalant use disorder, Moderate Inhalant use disorder, Severe F18.20 Inhalant dependence with intoxication delirium Inhalant dependence with intoxication delirium Inhalant dependence with intoxication delirium Inhalant intoxication, With moderate or severe use disorder<	F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder,
use disorderPhencyclidine-induced psychotic disorder, With moderate or severe use disorderF16.280Hallucinogen induced anxiety disorder, With moderate or severe use disorderPhencyclidine-induced anxiety disorder, With moderate or severe use disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.19Inhalant abuse, uncomplicated Inhalant abuse with inhalant-induced psychotic disorderF18.19Inhalant abuse with inhalant-induced psychotic disorder Inhalant abuse with inhalant-induced anxiety disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorderF18.180Inhalant abuse with other inhalant-induced disorderF18.181Inhalant abuse with other inhalant-induced disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant use disorder, SevereF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant intoxication, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder		
Phencyclidine-induced psychotic disorder, With moderate or severe use disorderF16.280Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorderF16.280Hallucinogen-induced anxiety disorder, With moderate or severe use disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.159Inhalant abuse, uncomplicated Inhalant induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant intoxication, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder		
disorderF16.280Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.159Inhalant abuse, uncomplicated Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant abuse with inhalant-induced psychotic disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with inhalant-induced mood disorder Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic		
F16.280 Hallucinogen dependence with hallucinogen-induced anxiety disorder Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder Phencyclidine-induced anxiety disorder, With moderate or severe use disorder F18.10 Inhalant abuse, uncomplicated Inhalant abuse, uncomplicated Inhalant use disorder, Mild Inhalant abuse with inhalant-induced psychotic disorder, unspecified F18.159 Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant abuse with inhalant-induced anxiety disorder Inhalant abuse with inhalant-induced anxiety disorder F18.180 Inhalant abuse with other inhalant-induced disorder Inhalant dependence, uncomplicated Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, Severe F18.221 Inhalant dependence with intoxication delirium Inhalant intoxication, With moderate or severe use disorder F18.229 Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorder F18.24 Inhalant dependence with inhalant-induced mood disorder Inhalant intoxication, With moderate or severe use disorder F18.259 Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant dependence with inhalant-induced psych		
Other hallucinogen-induced anxiety disorder, With moderate or severe use disorderPhencyclidine-induced anxiety disorder, With moderate or severe use disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.19Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, 		
disorderPhencyclidine-induced anxiety disorder, With moderate or severe use disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.159Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F16.280	0 1 0 5
Phencyclidine-induced anxiety disorder, With moderate or severe use disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.159Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.188Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Noderate Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified		
disorderF18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.159Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.29Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.29Inhalant dependence with inhalant-induced mood disorderF18.29Inhalant dependence with inhalant-induced mood disorderF18.29Inhalant dependence with inhalant-induced mood disorderF18.24Inhalant dependence with inhalant-induced mood disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder		
F18.10Inhalant abuse, uncomplicated Inhalant use disorder, MildF18.159Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.180Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder		
Inhalant use disorder, MildF18.159Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant-induced anxiety disorder, With mild use disorder Inhalant-induced anxiety disorder, With mild use disorderF18.188Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication, unspecified Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with inhalant-induced mood disorderF18.24Inhalant dependence with inhalant-induced mood disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	T 10.10	
F18.159Inhalant abuse with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.188Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant dependence with intoxication delirium Inhalant intoxication delirium Inhalant intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.229Inhalant dependence with inhalant-induced mood disorder Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18.10	·
Inhalant-induced psychotic disorder, With mild use disorderF18.180Inhalant abuse with inhalant-induced anxiety disorderF18.180Inhalant-induced anxiety disorder, With mild use disorderF18.188Inhalant abuse with other inhalant-induced disorderF18.188Inhalant abuse with other inhalant-induced disorderF18.180Inhalant abuse with other inhalant-induced disorderF18.20Inhalant dependence, uncomplicatedF18.20Inhalant use disorder, ModerateInhalant use disorder, SevereF18.21Inhalant dependence with intoxication deliriumInhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecifiedF18.24Inhalant dependence with inhalant-induced mood disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecifiedF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified	F10.150	
F18.180Inhalant abuse with inhalant-induced anxiety disorder Inhalant-induced anxiety disorder, With mild use disorderF18.188Inhalant abuse with other inhalant-induced disorder Inhalant abuse with other inhalant-induced disorderF18.188Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18.159	
Inhalant-induced anxiety disorder, With mild use disorderF18.188Inhalant abuse with other inhalant-induced disorderInhalant induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicatedInhalant use disorder, ModerateInhalant use disorder, SevereF18.21Inhalant dependence with intoxication deliriumInhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecifiedInhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder,	F10 100	
F18.188Inhalant abuse with other inhalant-induced disorder Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.21Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18.180	•
Inhalant-induced mild neurocognitive disorder, With mild use disorderF18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified	E 10 100	
F18.20Inhalant dependence, uncomplicated Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified	Г10.100	
Inhalant use disorder, Moderate Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	E18 20	
Inhalant use disorder, SevereF18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	110.20	
F18.221Inhalant dependence with intoxication delirium Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder		·
Inhalant intoxication delirium, With moderate or severe use disorderF18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, Unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18 221	
F18.229Inhalant dependence with intoxication, unspecified Inhalant intoxication, With moderate or severe use disorderF18.24Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorderF18.259Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	1 10.221	-
Inhalant intoxication, With moderate or severe use disorder F18.24 Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorder F18.259 Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18 229	
F18.24 Inhalant dependence with inhalant-induced mood disorder Inhalant-induced depressive disorder, With moderate or severe use disorder F18.259 Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	1 10.22	
Inhalant-induced depressive disorder, With moderate or severe use disorder F18.259 Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18.24	
disorder F18.259 Inhalant dependence with inhalant-induced psychotic disorder, unspecified Inhalant-induced psychotic disorder, With moderate or severe use disorder	1 1012 1	
F18.259 <i>Inhalant dependence with inhalant-induced psychotic disorder,</i> <i>unspecified</i> Inhalant-induced psychotic disorder, With moderate or severe use disorder		L
<i>unspecified</i> Inhalant-induced psychotic disorder, With moderate or severe use disorder	F18.259	
Inhalant-induced psychotic disorder, With moderate or severe use disorder		
		Inhalant-induced psychotic disorder, With moderate or severe use disorder
	F18.280	Inhalant dependence with inhalant-induced anxiety disorder
Inhalant-induced anxiety disorder, With moderate or severe use disorder		1

ICD-10-CM Code	Description
F18.288	Inhalant dependence with other inhalant-induced disorder
	Inhalant-induced mild neurocognitive disorder, With moderate or severe
	use disorder
F19.10	Other psychoactive substance abuse, uncomplicated
	Other (or unknown) substance use disorder, Mild
F19.20	Other psychoactive substance dependence, uncomplicated
	Other (or unknown) substance use disorder, Moderate
	Other (or unknown) substance use disorder, Severe

Secure Detoxification

What is secure detoxification (secure detox)?

Secure detoxification (secure detox) includes services provided in a secure detoxification facility certified to provide evaluation and assessment by chemical dependency professionals (CDPs), withdrawal management treatment, treatment as tolerated, discharge assistance, and has security measures sufficient to protect patients, staff, and the community. Treatment provided is for people who meet Involuntary Treatment Act (ITA) criteria due to a substance use disorder (RCW 71.05). An adult or minor may be committed for involuntary chemical dependency treatment upon petition of a designated crisis responder (DCR) if the person is "gravely disabled or presenting the likelihood of serious harm to self or others due to a substance use disorder."

Who is eligible for secure detox?

Secure detox services are available for eligible Apple Health clients who are not enrolled in a behavioral health organization (BHO), fully integrated managed care (FIMC), or behavioral health services only (BHSO) and have one of the following recipient aid categories (RACs):

1014-1023	1039	1046-1049
1052-1055	1059	1061
1065-1074	1083	1084
1086	1088-1091	1101-1111
1121	1122	1124
1126	1134	1146-1154
1156	1162-1069	1174-1177
1179	1180	1182-1207
1209	1211-1213	1217-1269

Note: For authorization requirements and information regarding secure detox for patients enrolled in a behavioral health organization (BHO), fully integrated managed care plan (FIMC) or behavioral health services only (BHSO), contact the corresponding entity.

Who is eligible to provide and bill for secure detox services?

To be eligible to provide and bill the agency for secure detox services described above, the provider must:

- Be licensed and certified by Department of Health (DOH) to provide the services;
- Be in good standing without restriction;
- Have a current core provider agreement (CPA) with the agency and national provider identifier (NPI). For more information about completing the CPA, see the <u>Provider</u> <u>Enrollment</u> webpage for new providers; and
- Be registered with the provider entry portal (PEP). See the <u>Contractor and provider</u> <u>resources</u> webpage.

What authorization is required?

Authorization is not required for Apple Health-eligible clients with the recipient aid categories (RACs) referenced in the <u>Who is eligible for secure detox?</u> section.

How do I bill for secure detox services?

For dates of service on and after July 1, 2018, submit claims for secure detox services on an electronic institutional claim form (837i) using the following information:

Name	Entry
Taxonomy	324500000X
Revenue Code	1002
Type of Facility	8
Bill Classification	6X